Y-MABS THERAPEUTICS INC (YMAB) Stock Fundamental Analysis

NASDAQ:YMAB • US9842411095

8.61 USD
+0.02 (+0.23%)
At close: Sep 15, 2025
8.61 USD
0 (0%)
After Hours: 9/15/2025, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall YMAB gets a fundamental rating of 4 out of 10. We evaluated YMAB against 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for YMAB as it has an excellent financial health rating, but there are worries on the profitability. YMAB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year YMAB has reported negative net income.
  • In the past year YMAB has reported a negative cash flow from operations.
  • In the past 5 years YMAB always reported negative net income.
  • In the past 5 years YMAB always reported negative operating cash flow.
YMAB Yearly Net Income VS EBIT VS OCF VS FCFYMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -18.96%, YMAB is in the better half of the industry, outperforming 77.59% of the companies in the same industry.
  • The Return On Equity of YMAB (-25.40%) is better than 80.74% of its industry peers.
Industry RankSector Rank
ROA -18.96%
ROE -25.4%
ROIC N/A
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
YMAB Yearly ROA, ROE, ROICYMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • With an excellent Gross Margin value of 81.78%, YMAB belongs to the best of the industry, outperforming 85.37% of the companies in the same industry.
  • YMAB's Gross Margin has declined in the last couple of years.
  • YMAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
YMAB Yearly Profit, Operating, Gross MarginsYMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • YMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for YMAB has been increased compared to 1 year ago.
  • The number of shares outstanding for YMAB has been increased compared to 5 years ago.
  • There is no outstanding debt for YMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
YMAB Yearly Shares OutstandingYMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
YMAB Yearly Total Debt VS Total AssetsYMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • YMAB has an Altman-Z score of 2.71. This is not the best score and indicates that YMAB is in the grey zone with still only limited risk for bankruptcy at the moment.
  • YMAB's Altman-Z score of 2.71 is fine compared to the rest of the industry. YMAB outperforms 69.81% of its industry peers.
  • YMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACC9.9%
YMAB Yearly LT Debt VS Equity VS FCFYMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 4.00 indicates that YMAB has no problem at all paying its short term obligations.
  • YMAB's Current ratio of 4.00 is in line compared to the rest of the industry. YMAB outperforms 45.74% of its industry peers.
  • YMAB has a Quick Ratio of 3.58. This indicates that YMAB is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of YMAB (3.58) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4
Quick Ratio 3.58
YMAB Yearly Current Assets VS Current LiabilitesYMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 10.71% over the past year.
  • Looking at the last year, YMAB shows a decrease in Revenue. The Revenue has decreased by -1.34% in the last year.
  • The Revenue has been growing by 35.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)-1.34%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%-14.36%

3.2 Future

  • Based on estimates for the next years, YMAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.75% on average per year.
  • The Revenue is expected to grow by 17.88% on average over the next years. This is quite good.
EPS Next Y-24.97%
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%
EPS Next 5Y9.75%
Revenue Next Year-5.98%
Revenue Next 2Y3.28%
Revenue Next 3Y6.75%
Revenue Next 5Y17.88%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
YMAB Yearly Revenue VS EstimatesYMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
YMAB Yearly EPS VS EstimatesYMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • YMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YMAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YMAB Price Earnings VS Forward Price EarningsYMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YMAB Per share dataYMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as YMAB's earnings are expected to decrease with -17.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • YMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Y-MABS THERAPEUTICS INC

NASDAQ:YMAB (9/15/2025, 8:00:02 PM)

After market: 8.61 0 (0%)

8.61

+0.02 (+0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08
Earnings (Next)11-06
Inst Owners82.83%
Inst Owner Change-100%
Ins Owners0.34%
Ins Owner Change-1015.42%
Market Cap391.24M
Revenue(TTM)85.39M
Net Income(TTM)-22.22M
Analysts53.75
Price Target8.2 (-4.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.27%
Min EPS beat(2)44.37%
Max EPS beat(2)74.16%
EPS beat(4)3
Avg EPS beat(4)25.03%
Min EPS beat(4)-18.84%
Max EPS beat(4)74.16%
EPS beat(8)5
Avg EPS beat(8)16.37%
EPS beat(12)9
Avg EPS beat(12)28.96%
EPS beat(16)10
Avg EPS beat(16)18.43%
Revenue beat(2)2
Avg Revenue beat(2)4.3%
Min Revenue beat(2)4.07%
Max Revenue beat(2)4.54%
Revenue beat(4)2
Avg Revenue beat(4)-4.6%
Min Revenue beat(4)-22.2%
Max Revenue beat(4)4.54%
Revenue beat(8)3
Avg Revenue beat(8)-3.53%
Revenue beat(12)7
Avg Revenue beat(12)4.86%
Revenue beat(16)7
Avg Revenue beat(16)0.93%
PT rev (1m)0%
PT rev (3m)-44.03%
EPS NQ rev (1m)3.14%
EPS NQ rev (3m)22.86%
EPS NY rev (1m)0%
EPS NY rev (3m)18.15%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)0.02%
Revenue NY rev (1m)0.45%
Revenue NY rev (3m)0.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.58
P/FCF N/A
P/OCF N/A
P/B 4.47
P/tB 4.59
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.88
BVpS1.93
TBVpS1.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.96%
ROE -25.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.78%
FCFM N/A
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4
Quick Ratio 3.58
Altman-Z 2.71
F-Score4
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-24.97%
EPS Next 2Y-19.37%
EPS Next 3Y-17.71%
EPS Next 5Y9.75%
Revenue 1Y (TTM)-1.34%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%-14.36%
Revenue Next Year-5.98%
Revenue Next 2Y3.28%
Revenue Next 3Y6.75%
Revenue Next 5Y17.88%
EBIT growth 1Y9.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.69%
EBIT Next 3Y-14.78%
EBIT Next 5YN/A
FCF growth 1Y60.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.1%
OCF growth 3YN/A
OCF growth 5YN/A

Y-MABS THERAPEUTICS INC / YMAB FAQ

What is the fundamental rating for YMAB stock?

ChartMill assigns a fundamental rating of 4 / 10 to YMAB.


What is the valuation status of Y-MABS THERAPEUTICS INC (YMAB) stock?

ChartMill assigns a valuation rating of 0 / 10 to Y-MABS THERAPEUTICS INC (YMAB). This can be considered as Overvalued.


Can you provide the profitability details for Y-MABS THERAPEUTICS INC?

Y-MABS THERAPEUTICS INC (YMAB) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for YMAB stock?

The Earnings per Share (EPS) of Y-MABS THERAPEUTICS INC (YMAB) is expected to decline by -24.97% in the next year.